60 results about "Ear infection" patented technology

A pharmaceutical or cosmeceutical foamable composition for topical application of vitamin D3 analogues such as calcipotriene and a process of manufacturing the same is disclosed. A method of treatment of skin and scalp disorders, especially of psoriasis or ear infections, by dispensing vitamin D3 analogues such as calcipotriene in a foamable composition is also disclosed.

A pharmaceutical composition is provided comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier; and having an antibacterial substance in an antibacterially effective amount stably dispersed in the vehicle. The composition is suitable for administration by intramammary infusion to a milk producing animal for treatment and/or prevention of mastitis or other diseases of the udder, as well as for otic administration for treatment and/or prevention of an ear infection.

The present invention relates to compositions and methods for treatment of ear infections and inflammation. Specifically, the method involves administering to a patient a composition containing an antibacterial, an anti-inflammatory, and an anti-septic that is substantially free of pramoxine to treat the occurrence or negative effects of otic infection and inflammation.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, and antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a fluoroquinolone, a triazole antifungal, a thiocarbamate antifungal, a corticosteroid and a polyene antifungal, as well as a thickener such that the formulation, upon applying to the infected ear canal, gels and remains in the ear canal, continuously releasing the active ingredients for several days, achieving consistent complete (98-100%) clinical resolution of otomycosis and otitis externa in a single application.

Efflux pump inhibitors are co-administered with antimicrobial agents for the treatment of ophthalmic or otic infections. The agents may be co-administered directly to the site of infection (e.g., the eye or ear).

A slow-dissolving troche with polyol molecules is disclosed. It may be an adherent troche, preferably adhered to teeth or gums or cheek with acacia gum, or a lollipop or child's pacifier. Consumers are instructed to use the troches at the end of each day and after each meal, at least four times per day to benefit oral health, particularly caries, gingivitis, periodontitis, ear infections, sinus infections, halitosis and risk of Streptococcus mutans infecting their blood from their mouths. The polyol molecules are preferably xylitol. The troches may be made with a bi-layer tablet press rounded on one side and flat on the other, preferably using acacia gum in the flat side layer for adhesion.

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

Optical ear infection treatment device and methods are described where an LED and optical light pipe are used to deliver the light from the LED to the middle ear of a patient to reduce bacterial growth and/or eliminate bacteria. Typically, the device is placed in the ear and then activated by the user by pressing an activation button. Once activated the control electronics will turn on the LED and perform a treatment. The most basic treatment mode comprises turning on the LED at maximum power for a predetermined period, e.g. 30 minutes, 60 minutes. When the preset duration is completed, the device will notify the user by an audible beep or vibration that the treatment is complete. Once completed, the user can remove the device, the treatment could be repeated once a day or for extreme cases multiple times during the day.

Topical otic pharmaceutical compositions comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof and a proteolytic enzyme. The compositions facilitate trans-tympanic delivery of a therapeutic level of the moxifloxacin.

The present application concerns a device for measurement and analysis of the middle ear and ear channel colour for the diagnosis of ear infections. The device is composed of a otoscope (1), including two optical fibers (2a and 2b): one for ear illumination and another returning the reflected light. The electronic unit (3) can change linearly the power of emitted light, as well as, its colour. The received light is also independently measured, enabling the determination of changes on colour and texture associated with the ear inflammations. Command buttons in the otoscope handler (4) enable the user to save the values of the three colour components. The combined value of the components is shown in the digital display (5) of the electronic unit, as well as, by a set of LEDs (6) green, yellow and red that gives a diagnosis in a simple and immediate way. The otoscope allows, simultaneously, directly ear view through a magnifying glass (7) applied in the head of the otoscope, with a standard white light. This device is also useful in food industry.

An inclined pulmonary-assisting mattress with a profile assisting infants and small children with respiratory problems and other adverse medical conditions, including asthma, wheezing, colic, SIDS, ear infections, and acid reflux. It can be used with a crib, bassinette, or other defined infant sleeping area, as long as it appropriately fills that sleeping area to eliminate all injury, entrapment, or breathing obstruction risk for the child using it. The mattress is not used on top of a crib mattress, but instead replaces a crib mattress until the child recovers or outgrows the breathing difficulty or adverse medical condition. At such time, the inclined pulmonary-assisting mattress is removed and the child is allowed to sleep on a regular crib mattress or other substantially horizontal surface. Intended applications include, but are not limited to, use in hospital neo-natal units, children's nurseries, and by parents of infants suffering from breathing or digestive issues.

A method of treating a mammal presenting with an otic infection attributable to a pathogenic bacteria is accomplished by passing a hollow shaft having a first and second end through the tympanum of the mammal. The first end is sufficient to pierce the tympanic membrane, but flexible enough such that it buckles under the force necessary to damage any surrounding tissues in the tympanic cavity. The first end of the hollow shaft, after it pierces the tympanic membrane, extends into the tympanic cavity to aspirate a volume of effluence contained therein. The aspirated effluence is expelled out the second end of the hollow shaft. A volume of medicament (less than the volume of effluence withdrawn) is then injected through the same hollow shaft and into the tympanic cavity to treat the infection.

The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.

A composition for removal of biofilm in the ears is useful for the treatment of ear infections such as otitis media, particularly those infections caused by Pseudomonas aeruginosa. In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down biofilm in the ear; and (2) a pharmaceutically acceptable carrier suitable for administration into the ear canal. The composition can further include ingredients such as a steroid, lysozyme, lactoferrin, or a peroxidase; if a peroxidase is included, the composition can further include an oxidase to generate peroxide as well as a substrate for the oxidase. The composition can be used in methods for treatment of an ear infection based on the ability of the composition to dissolve biofilm in the ear.

The present invention relates to the treatment of Otis infection of the ear or other infection of the ear by application of blue violet light. The device of the present invention operates hands free mounting over the ear in such a way to provide light treatments without the need to hold the device by positioning the light source such that the light is positioned to shine into the ear canal.

Disclosed herein is an improved composition that is useful in treating otic infections comprising an antimicrobial and silver sulfadiazine in a therapeutically effective combination to treat otic infections in animals, the improvement comprising the composition which can be used safely to treat animals with a ruptured tympanic membrane.

The invention concerns a composition and method for treating an otic infection, including otitis externa or otitis media, the composition comprising povidone iodine and dimethylsulfoxide (DMSO) and, optionally, a gelling agent.

The present invention relates generally to a methods of treating ear infections and clearing excess fluid from Eustachian tubes.